指南与共识介入腹部DSACTMR

肝细胞癌经动脉化疗栓塞:2023年韩国肝癌协会基于专家共识的实践推荐

Transarterial chemoembolization for hepatocellular carcinoma: 2023 Expert consensus-based practical recommendations of the Korean Liver Cancer Association.
指南 / 共识 · Clin Mol Hepatol · 2023-07-01

韩国肝癌协会研究委员会召集12名介入放射学与肝病学专家,制定肝细胞癌经动脉化疗栓塞(TACE)的专家共识实践推荐,涵盖患者准备、操作技术和治疗后护理,旨在提高疗效与安全性,并获韩国介入放射学会认可。

要点

  • TACE是适合根治性治疗之外的肝细胞癌患者常用的非手术治疗方式。
  • 共识推荐涉及患者准备、操作技术和治疗后护理,以提升疗效与安全性。
  • 推荐由韩国肝癌协会研究委员会组织12名专家制定,获韩国介入放射学会认可。

核心结论

  • 该共识为TACE的患者准备、操作技术和治疗后护理提供实践推荐,以增强疗效与安全性。

研究设计与样本

  • 韩国肝癌协会研究委员会召集12名介入放射学和肝病学专家制定专家共识推荐,获韩国介入放射学会认可。

临床应用与阅片要点

  • 推荐涉及TACE患者准备、操作技术和治疗后护理,旨在提高疗效与安全性。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Transarterial chemoembolization (TACE) was introduced in 1977 with the administration of chemotherapeutic agent to gelatin sponge particles through the hepatic artery in patients with hepatocellular carcinoma (HCC) and was established as conventional TACE using Lipiodol in the 1980s. In the 2000s, drug-eluting beads were developed and applied clinically. Currently, TACE is a commonly used non-surgical treatment modality for patients with HCC who are unsuitable for curative treatment. Considering the vital role of TACE in the management of HCC, it is crucial to organize current knowledge and expert opinions regarding patient preparation, procedural techniques, and post-treatment care in TACE, which can enhance therapeutic efficacy and safety. A group of 12 experts in the fields of interventional radiology and hepatology, convened by the Research Committee of the Korean Liver Cancer Association (KLCA), has developed expert consensus-based practical recommendations in TACE. These recommendations have been endorsed by the Korean Society of Interventional Radiology and provide useful information and direction in performing TACE procedure as well as pre- and post- procedural patient care.

来源:Clin Mol Hepatol,查看原文。版权归原作者所有。

引用

  1. Cho Y, Choi JW, Kwon H, et al. Transarterial chemoembolization for hepatocellular carcinoma: 2023 Expert consensus-based practical recommendations of the Korean Liver Cancer Association. Clin Mol Hepatol. 2023. PMID: 37482892. doi:10.3350/cmh.2023.0202

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。